Gilead Sciences Inc. (NASDAQ:GILD) received a $108.00 price objective from research analysts at Piper Jaffray Cos. in a research report issued on Thursday. The brokerage currently has a a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Cos.’s price target suggests a potential upside of 32.48% from the company’s current price.

A number of other equities analysts have also recently issued reports on the stock. Jefferies Group restated a “buy” rating and issued a $91.00 price objective on shares of Gilead Sciences in a research note on Thursday. Berenberg Bank began coverage on shares of Gilead Sciences in a research note on Thursday. They issued a “buy” rating for the company. Zacks Investment Research upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, September 14th. Credit Suisse Group AG dropped their price objective on shares of Gilead Sciences from $115.00 to $95.00 and set an “outperform” rating for the company in a research note on Wednesday, September 14th. Finally, Morgan Stanley set a $100.00 price objective on shares of Gilead Sciences and gave the company a “hold” rating in a research note on Tuesday, September 6th. Nine investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $105.41.

Gilead Sciences (NASDAQ:GILD) traded up 0.10% on Thursday, reaching $81.60. 3,800,129 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $79.41 and a 200-day moving average of $85.94. The firm has a market capitalization of $107.68 billion, a price-to-earnings ratio of 7.16 and a beta of 1.06. Gilead Sciences has a 12 month low of $76.67 and a 12 month high of $111.11.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. During the same period in the prior year, the firm earned $3.15 EPS. The business’s revenue was down 5.7% on a year-over-year basis. On average, equities analysts expect that Gilead Sciences will post $11.77 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.31%. Gilead Sciences’s dividend payout ratio (DPR) is presently 16.56%.

In related news, CEO John F. Milligan sold 112,000 shares of the business’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the transaction, the chief executive officer now directly owns 1,170,963 shares in the company, valued at $98,747,309.79. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Paul Rutherford Carter sold 2,000 shares of the business’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $83.12, for a total transaction of $166,240.00. Following the transaction, the executive vice president now owns 63,122 shares in the company, valued at $5,246,700.64. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.

A number of institutional investors have recently modified their holdings of the company. Van Hulzen Asset Management LLC increased its position in shares of Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 100 shares during the last quarter. Joel Isaacson & Co. LLC increased its position in shares of Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 226 shares during the last quarter. Roble Belko & Company Inc increased its position in shares of Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,035 shares during the last quarter. Pinkerton Retirement Specialists LLC increased its position in shares of Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 1,582 shares during the last quarter. Finally, Jolley Asset Management LLC increased its position in shares of Gilead Sciences by 67.3% in the second quarter. Jolley Asset Management LLC now owns 1,696 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 682 shares during the last quarter. Institutional investors and hedge funds own 77.94% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.